Skip to content

TRVI - Trevi Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchT

Trevi Therapeutics Inc

TRVI · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

T

TRVITrevi Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $20.22
52-wk low: $6.93
Prev close: $13.45
Mkt cap: $2.68B
Beta: 1.07
P/B: 8.3x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$636.2M

MW
Marshall Wace
Q2 2026 13F
$49.9M
position
VG
Viking Global
Andreas Halvorsen · Q2 2026 13F

Earnings

Reported Aug 6, 2026

Earnings landed in line with what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.7B

Valuation

P/B8.35

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: TRVI
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $2.68B
Beta: 1.07

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-19.7%

$28.8M

position

BA

Balyasny

Dmitry Balyasny · Q2 2026 13F

$15.8M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for TRVI

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.11+0.0%

-$0.11 expected

Next report

What the street expects next

-19.7%

ROA-13.8%

Growth

Beta1.07